CAMBRIDGE, Mass., Nov. 4, 2013 /PRNewswire/ -- Seventh Sense Biosystems, Inc., the leading developer of painless blood collection and diagnostic platforms, today announced it has obtained CE Mark approval for its Touch Activated Phlebotomy (TAP™) platform for blood collection and testing.
"This first regulatory approval is a significant milestone in our goal of expanding the reach of blood-based point-of-care diagnostics to a majority of patients, regardless of geography or setting," said Howard Weisman, CEO and President of Seventh Sense. "When fully commercialized, the TAP platform will incorporate additional capabilities for sample separation as well as dried blood spot and on-board diagnostic capabilities."
Studies show that a positive patient experience is closely linked to compliance with a prescribed treatment. Seventh Sense will be developing and commercializing novel diagnostic tools that are specially engineered to eliminate the pain and anxiety that can prevent patients from receiving appropriate care. The company's proprietary innovations in microneedle and microfluidic technology enable the collection of a stable, secure and high quality blood sample without painful lancing or the need for highly skilled medical personnel.
"We've surveyed patients and their physicians around the world and found a significant need for near painless, simple-to-use, and reliable blood collection and diagnostic devices that has so far been unmet," said Weisman.
The company plans to scale-up manufacturing capability in 2014 and continue the development of follow-on products for patients and clinicians in the Americas, Europe and Asia-Pacific regions.
About the Touch Activated Phlebotomy Device
Touch Activated Phlebotomy (TAP™) is a proprietary platform that draws capillary blood in a painless, one-step process without having to access a vein and it can be utilized across and integrated with a broad spectrum of diagnostic applications. The TAP system penetrates the uppermost layers of skin through the use of micro-needles, collects capillary blood using a novel microfluidic extraction process, and stabilizes the blood with anticoagulant if required. The device has a visual indicator to confirm that collection is complete. The TAP platform is designed for fully automated, high throughput manufacturing.
About Seventh Sense Biosystems, Inc.
Founded in 2008, within Flagship VentureLabs™, Seventh Sense is developing an array of products based on the company's proprietary Touch Activated Phlebotomy (TAP™) painless blood collection platform, with an initial focus on enabling important diagnostic testing at the point of care by reducing the discomfort, anxiety and hassle of blood sample collection. Seventh Sense is backed by leading investors Flagship Ventures and Polaris Partners. For more information, please visit www.7sbio.com.
For media inquiries contact:
617-547-7246 ext. 222
SOURCE Seventh Sense Biosystems, Inc.